BTK and autoimmune disease: A number of BTK inhibitors have shown efficacy in several preclinical models of inflammatory or autoimmune diseases that are driven by pathogenic B cells or myeloid cells and several molecules have progressed into clinical trials, but thus far there are no approved BTK inhibitors for inflammatory or autoimmune disorders.